Senseonics Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Senseonics Holdings, Inc.
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.
Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market.
Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
- Digital Health
- Implantable Devices
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
- ASN Technologies, Inc
- Sensors for Medicine and Science, Inc.
- Senseonics, Incorporated
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.